-
1دورية أكاديمية
المؤلفون: García-Donas, Jesús, Martínez-Urbistondo, Diego, Velázquez Kennedy, Kyra, Villares, Paula, Barquin, Arántzazu, Domínguez, Andrea, Rodríguez-Moreno, Juan Francisco, Caro, Elena, Suárez del Villar, Rafael, Nistal-Villan, Estanislao, Yagüe, Mónica, Ortiz, Maria, Barba, Maria, Ruiz-Llorente, Sergio, Quiralte, Miguel, Zanin, Massimiliano, Rodríguez, Cristina, Navarro, Paloma, Berraondo, Pedro, Madurga, Rodrigo
المساهمون: Novartis, Instituto de Salud Carlos III, European Research Council, Ministerio de Ciencia e Innovación (España), Agencia Estatal de Investigación (España), Nafarroako Gobernua
مصطلحات موضوعية: Simvastatin, COVID19, SARS-Cov-2, Clinical trial, Cytokine storm, Ruxolitinib
وصف الملف: application/pdf
العلاقة: #PLACEHOLDER_PARENT_METADATA_VALUE#; info:eu-repo/grantAgreement/EC/H2020/851255; info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023/CEX2021-001164-M; Publisher's version; García-Donas, Jesús; Martínez-Urbistondo, Diego; Velázquez Kennedy, Kyra; Villares, Paula; Barquin, Arántzazu; Domínguez, Andrea; Rodríguez-Moreno, Juan Francisco; Caro, Elena; Suárez del Villar, Rafael; Nistal-Villan, Estanislao; Yagüe, Mónica; Ortiz, Maria; Barba, Maria; Ruiz-Llorente, Sergio; Quiralte, Miguel; Zanin, Massimiliano; Rodríguez, Cristina; Navarro, Paloma; Berraondo, Pedro; Madurga, Rodrigo; 2023; DataSheet_1_Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution.pdf [Dataset]; Figshare; https://doi.org/10.3389/fimmu.2023.1156603.s001Test; Navarro, Paloma; Berraondo, Pedro; Madurga, Rodrigo; 2023; Table_1_Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution.xlsx [Dataset]; Figshare; https://doi.org/10.3389/fimmu.2023.1156603.s002Test; https://doi.org/10.3389/fimmu.2023.1156603Test; Sí; Frontiers in Immunology 14: 1156603 (2023); CEX2021-001164-M; http://hdl.handle.net/10261/352169Test; http://dx.doi.org/10.13039/100004336Test; http://dx.doi.org/10.13039/501100011033Test; http://dx.doi.org/10.13039/501100000781Test; http://dx.doi.org/10.13039/501100004587Test; http://dx.doi.org/10.13039/501100004837Test; 2-s2.0-85159553059; https://api.elsevier.com/content/abstract/scopus_id/85159553059Test
الإتاحة: https://doi.org/10.3389/fimmu.2023.115660310.13039/10000433610.13039/50110001103310.13039/50110000078110.13039/50110000458710.13039/50110000483710.3389/fimmu.2023.1156603.s00110.3389/fimmu.2023.1156603.s002Test
http://hdl.handle.net/10261/352169Test
https://api.elsevier.com/content/abstract/scopus_id/85159553059Test -
2دورية أكاديمية
المؤلفون: Quiralte, Miguel1,2, Barquín, Arantzazu1,3, Yagüe-Fernández, Mónica1, Navarro, Paloma1,2, Grazioso, Tatiana P.1, Sevillano-Fernández, Elena1,3, Rodriguez-Moreno, Juan F.1,3, Balarezo-Saldivar, Alejandra1,2, Peinado, Héctor4, Izquierdo, Elena2, Millán, Carlos5, López-Carrasco, Irene5, Prieto, Mario6, Madurga, Rodrigo7, Fernández-Miranda, Ismael8, Ruiz-Llorente, Sergio1,9 sergio.ruizl@uah.es, García-Donas, Jesús1,2,3 jgarciadonas@hmhospitales.com
المصدر: Journal of Clinical Investigation. 5/15/2024, Vol. 134 Issue 10, p1-18. 18p.
مصطلحات موضوعية: *EXTRACELLULAR vesicles, *CANCER prognosis, *PROTEOMICS, *PROGNOSIS, *TUMOR microenvironment, *PERITONEUM diseases
-
3
المؤلفون: García-Donas, Jesús, Martínez-Urbistondo, Diego, Velázquez Kennedy, Kyra, Villares, Paula, Barquin, Arántzazu, Domínguez, Andrea, Rodríguez-Moreno, Juan Francisco, Caro, Elena, Suárez del Villar, Rafael, Nistal-Villan, Estanislao, Yagüe, Mónica, Ortiz, Maria, Barba, Maria, Ruiz-Llorente, Sergio, Quiralte, Miguel, Zanin, Massimiliano, Rodríguez, Cristina, Navarro, Paloma, Berraondo, Pedro, Madurga, Rodrigo
المساهمون: Caro, Elena, Ruiz-Llorente, Sergio, Zanin, Massimiliano
مصطلحات موضوعية: Clinical trial, COVID19, SARS-Cov-2, Cytokine storm, Ruxolitinib, Simvastatin
وصف الملف: application/vnd.ms-excel
العلاقة: García-Donas, Jesús; Martínez-Urbistondo, Diego; Velázquez Kennedy, Kyra; Villares, Paula; Barquin, Arántzazu; Domínguez, Andrea; Rodríguez-Moreno, Juan Francisco; Caro, Elena; Suárez del Villar, Rafael; Nistal-Villan, Estanislao; Yagüe, Mónica; Ortiz, Maria; Barba, Maria; Ruiz-Llorente, Sergio; Quiralte, Miguel; Zanin, Massimiliano; Rodríguez, Cristina; Navarro, Paloma; Berraondo, Pedro; Madurga, Rodrigo. Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution. https://doi.org/10.3389/fimmu.2023.1156603Test . http://hdl.handle.net/10261/352169Test; https://doi.org/10.3389/fimmu.2023.1156603.s002Test; Sí; Navarro, Paloma; Berraondo, Pedro; Madurga, Rodrigo; 2023; Table_1_Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution.xlsx [Dataset]; Figshare; https://doi.org/10.3389/fimmu.2023.1156603.s002Test; http://hdl.handle.net/10261/352174Test
الإتاحة: https://doi.org/10.3389/fimmu.2023.1156603.s002Test
https://doi.org/10.3389/fimmu.2023.1156603Test
http://hdl.handle.net/10261/352174Test -
4
المؤلفون: García-Donas, Jesús, Martínez-Urbistondo, Diego, Velázquez Kennedy, Kyra, Villares, Paula, Barquin, Arántzazu, Domínguez, Andrea, Rodríguez-Moreno, Juan Francisco, Caro, Elena, Suárez del Villar, Rafael, Nistal-Villan, Estanislao, Yagüe, Mónica, Ortiz, Maria, Barba, Maria, Ruiz-Llorente, Sergio, Quiralte, Miguel, Zanin, Massimiliano, Rodríguez, Cristina, Navarro, Paloma, Berraondo, Pedro, Madurga, Rodrigo
المساهمون: Caro, Elena, Ruiz-Llorente, Sergio, Zanin, Massimiliano
مصطلحات موضوعية: Clinical trial, COVID19, SARS-Cov-2, Cytokine storm, Ruxolitinib, Simvastatin
وصف الملف: application/pdf
العلاقة: García-Donas, Jesús; Martínez-Urbistondo, Diego; Velázquez Kennedy, Kyra; Villares, Paula; Barquin, Arántzazu; Domínguez, Andrea; Rodríguez-Moreno, Juan Francisco; Caro, Elena; Suárez del Villar, Rafael; Nistal-Villan, Estanislao; Yagüe, Mónica; Ortiz, Maria; Barba, Maria; Ruiz-Llorente, Sergio; Quiralte, Miguel; Zanin, Massimiliano; Rodríguez, Cristina; Navarro, Paloma; Berraondo, Pedro; Madurga, Rodrigo. Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution. https://doi.org/10.3389/fimmu.2023.1156603Test . http://hdl.handle.net/10261/352169Test; https://doi.org/10.3389/fimmu.2023.1156603.s001Test; Sí; Navarro, Paloma; Berraondo, Pedro; Madurga, Rodrigo; 2023; DataSheet_1_Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution.pdf [Dataset]; Figshare; https://doi.org/10.3389/fimmu.2023.1156603.s001Test; http://hdl.handle.net/10261/352172Test
الإتاحة: https://doi.org/10.3389/fimmu.2023.1156603.s001Test
https://doi.org/10.3389/fimmu.2023.1156603Test
http://hdl.handle.net/10261/352172Test -
5دورية أكاديمية
المؤلفون: Quiralte, Miguel, Barquin, Arantzazu, Yagüe, Monica, Navarro, Paloma, Sevillano, Elena, Rodriguez-Moreno, Juan Francisco, Balarezo, Alejandra, Peinado, Héctor, Izquierdo, Elena, Millan, Carlos, Lopez, Irene, Ruiz-Llorente, Sergio, García-Donas, Jesús
المصدر: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pe17561-e17561, 1p